Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 11Phase 2/3 3Phase NA 2Phase 1 2Phase 4 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Resectable Esophageal Cancer 1Rectal Neoplasms 1Pancreatic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Oxaliplatin 21Capecitabine 17Fluorouracil 15Irinotecan 11Radiotherapy 10Leucovorin 8Cetuximab 6Bevacizumab 6Gemcitabine 5oblimersen 3fludarabine 3aldesleukin 3Nivolumab 3Erlotinib Hydrochloride 3Cyclophosphamide 3labetuzumab 2dehydroftorafur 2conatumumab 2Tomography, X-Ray Computed 2Receptor Protein-Tyrosine Kinases 2Radiation 2Panitumumab 2Neoadjuvant Therapy 2Magnetic Resonance Imaging 2Interleukin-2 2Gefitinib 2Electrocardiography 2Diphenhydramine 25,10-methylenetetrahydrofolic acid 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rectal Neoplasms × Chemoradiotherapy × Clear all
NCT02948348 2021-09-16

Study to Nivolumab Following Preoperative Chemoradiotherapy

National Cancer Center Hospital East

Phase 1/2 Unknown
90 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡